Novartis India Ltd (NOVARTIND)
🎯 Key Takeaways
- Novartis India Ltd is in a phase of sustained growth driven by strong operational execution and expanding market presence in the domestic pharmaceutical sector. The company has demonstrated consistent profitability and margin resilience, supported by a disciplined cost structure and high operating leverage.
- Revenue grew 14.6% QoQ to ₹104 in Q1FY27.
- ⚠️ Exposure to regulatory and pricing pressures in the domestic pharmaceutical market remains a concern, particularly with regard to reimbursement polici
📖 The Story
Novartis India Ltd is in a phase of sustained growth driven by strong operational execution and expanding market presence in the domestic pharmaceutical sector. The company has demonstrated consistent profitability and margin resilience, supported by a disciplined cost structure and high operating leverage. Its financial trajectory reflects a mature yet growing business with scalable operations and strong cash generation.
📰 What's Happening
In Q1FY27, the company reported revenue of ₹104 crore with operating profit of ₹34 crore and an OPM of 33.2%, up from ₹91 crore revenue and ₹20 crore OP in Q3FY26. Management highlighted continued strong demand across therapeutic segments and successful product launches in chronic disease management. The company also announced a strategic expansion of its commercial operations to enhance market penetration in Tier 2 and Tier 3 cities. There were no changes in promoter holding or board composition during the quarter.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 88 | 90 | 86 | 91 | 104 |
| Operating Profit | 27 | 23 | 22 | 20 | 34 |
| OPM % | 30.5% | 25.9% | 25.5% | 22.3% | 33.2% |
| Net Profit | 28 | 24 | 16 | 25 | 32 |
| EPS | ₹11.19 | ₹9.81 | ₹6.52 | ₹10.23 | ₹13.05 |
Revenue has grown sequentially over the past four quarters, rising from ₹86 crore in Dec 2025 to ₹104 crore in Jun 2026, reflecting expanding sales momentum. Operating margins have improved from 22.3% in Mar 2026 to 33.2% in Jun 2026, indicating operating leverage and pricing power. Net profit rose to ₹32 crore in Q1FY27 from ₹16 crore in Dec 2025, with EPS increasing to ₹13.05, suggesting improved profitability and efficiency in operations.
🔮 Management Outlook & What's Next
Management has expressed confidence in sustaining double-digit growth over the medium term, citing a robust pipeline and expanding footprint in underserved markets. They emphasized continued investment in sales and marketing capabilities to drive volume growth while maintaining cost discipline. No specific revenue or margin guidance was provided in the latest filing, but strategic priorities remain focused on market expansion and product diversification.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 |
| Reserves | 717 | 773 | 763 | 805 |
| Borrowings | 6 | 5 | 4 | 0 |
| Total Liabilities | 891 | 948 | 932 | 978 |
| Fixed Assets | 6 | 5 | 4 | 3 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 891 | 948 | 932 | 978 |
The balance sheet remains strong with zero net debt and equity of ₹12 crore supported by reserves of ₹805 crore as of Mar 2026. Total assets have grown to ₹978 crore, up from ₹948 crore a year ago, reflecting operational expansion. Borrowings remain minimal at ₹3 crore, indicating a conservative capital structure and low financial risk.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2024 | Mar 2026 |
|---|---|---|
| Operating | +113 | +47 |
| Investing | +33 | +18 |
| Financing | -121 | -64 |
| Net Cash Flow | +26 | +0 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 70.7% | 70.7% | 70.7% |
| FII | 0.2% | 0.2% | 0.2% |
| DII | 0.6% | 0.5% | 1.4% |
| Public | 22.7% | 23.3% | 22.5% |
| # Shareholders | 39,468 | 38,116 | 36,502 |
Promoter holding remains stable at 70.68% over the last three quarters, signaling confidence in long-term prospects. FII shareholding has slightly declined from 0.19% to 0.16%, while DII increased from 0.53% to 1.35% in Q1FY27, suggesting growing institutional interest. The number of public shareholders has risen to 36,502, indicating retail investor engagement and share price stability.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.42 L Cr | 36.5 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.48 L Cr | 84.6 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.12 L Cr | 24.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.7 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.06 L Cr | 97.3 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 96,906 | 30.0 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 96,402 | 26.2 | 12.8% | 9.8% | 0.20 |
| LUPIN | 95,836 | 16.9 | 27.9% | 24.7% | 0.26 |
| MANKIND | 94,039 | 46.0 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
Exposure to regulatory and pricing pressures in the domestic pharmaceutical market remains a concern, particularly with regard to reimbursement policies and tenders. Management also flagged foreign exchange volatility as a potential headwind due to import dependency for certain formulations. Additionally, margin expansion may face pressure if input costs rise or competitive pricing intensifies in key therapeutic areas.
📋 Recent Filings
-
🔴 Announcement 11 September 2026Novartis India Limited announced its investor presentation for the September 11, 2026 analyst call, confirming no unpublished price-sensitive informat...
-
🔴 annual report 9 September 2026Novartis India announced that its 78th Annual General Meeting will be held on September 24, 2026 via video conference, and dispatched physical letters...
-
🔴 Announcement 8 September 2026Novartis India announced an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited to market retina drugs Accentrix a...
-
🔴 Announcement 8 September 2026Novartis India announced an analyst and institutional investor meeting scheduled for September 11, 2026, at 4:00 pm IST, conducted virtually and in pe...
-
🟡 Board Meeting 7 September 2026Novartis India approved the acquisition of Pfizer's Minipress and Minipres trademarks and related IP rights for INR 1250 crores and 10,000. The transa...
-
🟡 sustainability report 2 September 2026Novartis India Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on September 2, 2026, detailing ESG performan...
-
🟡 Board Meeting 2 September 2026The 78th Annual General Meeting of Novartis India Ltd is scheduled for September 24, 2026 via video conferencing. Shareholders will vote on key resolu...
-
🔴 annual report 2 September 2026Novartis India Ltd's 2025-26 Annual Report details the completion of a 70.68% stake sale to WaveRise, ChrysCapital Fund X, and Two Infinity Partners o...
🧠 Analyst's Read
Novartis India is executing a disciplined growth strategy with strong financial performance and improving margins, supported by a healthy balance sheet and stable promoter ownership. Investors should monitor execution of expansion plans and evolving regulatory dynamics in the domestic pharma sector as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-12.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when NOVARTIND files new disclosures
Track NOVARTIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NOVARTIND — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd